A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer

Wen Wei Sung, Yao Chen Wang, Ya Wen Cheng, Ming Ching Lee, Kun Tu Yeh, Lee Wang, John Wang, Chih Yi Chen, Huei Lee

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Purpose: Fas ligand (FasL) -844T/C polymorphism (rs763110) has a demonstrated association with lung cancer risk. FasL -844CC with higher FasL expression has been suggested to contribute to tumor progression via immune escape. However, the impact of FasL -844T/C polymorphism on the clinical outcome of non-small cell lung cancer (NSCLC) remains to be identified. Experimental Design: A total of 385 adjacent normal lung tissues from patients with NSCLC were collected to determine FasL -844T/C polymorphism by PCR-based restriction fragment length polymorphism. FasL mRNA and protein expression in lung tumors were evaluated by real-time PCR and immunohistochemistry. The prognostic value of FasL -844T/C polymorphism on survival and relapse was determined by Kaplan-Meier analysis and Cox proportional hazards models. Results: The FasL -844CC genotype had higher prevalence in those with advanced tumors than in those with early tumors (P = 0.008). In addition, patients with the FasL -844CC genotype were more prone to tumor relapse than those with the FasL -844TT+TC genotype (62.1% vs. 37.9%, P = 0.001). Multivariate Cox regression analysis showed that patients with the FasL -844CC genotype had poorer survival in terms of overall survival (OS) and relapse-free survival (RFS) than those with the FasL -844TT+TC genotype (24.1 vs. 42.8 months for OS, HR = 1.455, P = 0.004; 15.4 vs. 31.4 months for RFS, HR = 1.710, P <0.001). Conclusions: FasL -844T/C polymorphism may predict survival and relapse in NSCLC. We suggest that FasL may be a molecular target for immunotherapeutic interventions to improve the clinical outcome of patients with NSCLC. This finding should be validated by another investigative group.

Original languageEnglish
Pages (from-to)5991-5999
Number of pages9
JournalClinical Cancer Research
Volume17
Issue number18
DOIs
Publication statusPublished - Sep 15 2011
Externally publishedYes

Fingerprint

Fas Ligand Protein
Non-Small Cell Lung Carcinoma
Recurrence
Survival
Genotype
Neoplasms
Lung
Kaplan-Meier Estimate
Proportional Hazards Models
Restriction Fragment Length Polymorphisms
Real-Time Polymerase Chain Reaction
Lung Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sung, W. W., Wang, Y. C., Cheng, Y. W., Lee, M. C., Yeh, K. T., Wang, L., ... Lee, H. (2011). A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer. Clinical Cancer Research, 17(18), 5991-5999. https://doi.org/10.1158/1078-0432.CCR-11-0227

A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer. / Sung, Wen Wei; Wang, Yao Chen; Cheng, Ya Wen; Lee, Ming Ching; Yeh, Kun Tu; Wang, Lee; Wang, John; Chen, Chih Yi; Lee, Huei.

In: Clinical Cancer Research, Vol. 17, No. 18, 15.09.2011, p. 5991-5999.

Research output: Contribution to journalArticle

Sung, WW, Wang, YC, Cheng, YW, Lee, MC, Yeh, KT, Wang, L, Wang, J, Chen, CY & Lee, H 2011, 'A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer', Clinical Cancer Research, vol. 17, no. 18, pp. 5991-5999. https://doi.org/10.1158/1078-0432.CCR-11-0227
Sung, Wen Wei ; Wang, Yao Chen ; Cheng, Ya Wen ; Lee, Ming Ching ; Yeh, Kun Tu ; Wang, Lee ; Wang, John ; Chen, Chih Yi ; Lee, Huei. / A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer. In: Clinical Cancer Research. 2011 ; Vol. 17, No. 18. pp. 5991-5999.
@article{f76628690fa2428e874fcd4dbac2ba2f,
title = "A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer",
abstract = "Purpose: Fas ligand (FasL) -844T/C polymorphism (rs763110) has a demonstrated association with lung cancer risk. FasL -844CC with higher FasL expression has been suggested to contribute to tumor progression via immune escape. However, the impact of FasL -844T/C polymorphism on the clinical outcome of non-small cell lung cancer (NSCLC) remains to be identified. Experimental Design: A total of 385 adjacent normal lung tissues from patients with NSCLC were collected to determine FasL -844T/C polymorphism by PCR-based restriction fragment length polymorphism. FasL mRNA and protein expression in lung tumors were evaluated by real-time PCR and immunohistochemistry. The prognostic value of FasL -844T/C polymorphism on survival and relapse was determined by Kaplan-Meier analysis and Cox proportional hazards models. Results: The FasL -844CC genotype had higher prevalence in those with advanced tumors than in those with early tumors (P = 0.008). In addition, patients with the FasL -844CC genotype were more prone to tumor relapse than those with the FasL -844TT+TC genotype (62.1{\%} vs. 37.9{\%}, P = 0.001). Multivariate Cox regression analysis showed that patients with the FasL -844CC genotype had poorer survival in terms of overall survival (OS) and relapse-free survival (RFS) than those with the FasL -844TT+TC genotype (24.1 vs. 42.8 months for OS, HR = 1.455, P = 0.004; 15.4 vs. 31.4 months for RFS, HR = 1.710, P <0.001). Conclusions: FasL -844T/C polymorphism may predict survival and relapse in NSCLC. We suggest that FasL may be a molecular target for immunotherapeutic interventions to improve the clinical outcome of patients with NSCLC. This finding should be validated by another investigative group.",
author = "Sung, {Wen Wei} and Wang, {Yao Chen} and Cheng, {Ya Wen} and Lee, {Ming Ching} and Yeh, {Kun Tu} and Lee Wang and John Wang and Chen, {Chih Yi} and Huei Lee",
year = "2011",
month = "9",
day = "15",
doi = "10.1158/1078-0432.CCR-11-0227",
language = "English",
volume = "17",
pages = "5991--5999",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer

AU - Sung, Wen Wei

AU - Wang, Yao Chen

AU - Cheng, Ya Wen

AU - Lee, Ming Ching

AU - Yeh, Kun Tu

AU - Wang, Lee

AU - Wang, John

AU - Chen, Chih Yi

AU - Lee, Huei

PY - 2011/9/15

Y1 - 2011/9/15

N2 - Purpose: Fas ligand (FasL) -844T/C polymorphism (rs763110) has a demonstrated association with lung cancer risk. FasL -844CC with higher FasL expression has been suggested to contribute to tumor progression via immune escape. However, the impact of FasL -844T/C polymorphism on the clinical outcome of non-small cell lung cancer (NSCLC) remains to be identified. Experimental Design: A total of 385 adjacent normal lung tissues from patients with NSCLC were collected to determine FasL -844T/C polymorphism by PCR-based restriction fragment length polymorphism. FasL mRNA and protein expression in lung tumors were evaluated by real-time PCR and immunohistochemistry. The prognostic value of FasL -844T/C polymorphism on survival and relapse was determined by Kaplan-Meier analysis and Cox proportional hazards models. Results: The FasL -844CC genotype had higher prevalence in those with advanced tumors than in those with early tumors (P = 0.008). In addition, patients with the FasL -844CC genotype were more prone to tumor relapse than those with the FasL -844TT+TC genotype (62.1% vs. 37.9%, P = 0.001). Multivariate Cox regression analysis showed that patients with the FasL -844CC genotype had poorer survival in terms of overall survival (OS) and relapse-free survival (RFS) than those with the FasL -844TT+TC genotype (24.1 vs. 42.8 months for OS, HR = 1.455, P = 0.004; 15.4 vs. 31.4 months for RFS, HR = 1.710, P <0.001). Conclusions: FasL -844T/C polymorphism may predict survival and relapse in NSCLC. We suggest that FasL may be a molecular target for immunotherapeutic interventions to improve the clinical outcome of patients with NSCLC. This finding should be validated by another investigative group.

AB - Purpose: Fas ligand (FasL) -844T/C polymorphism (rs763110) has a demonstrated association with lung cancer risk. FasL -844CC with higher FasL expression has been suggested to contribute to tumor progression via immune escape. However, the impact of FasL -844T/C polymorphism on the clinical outcome of non-small cell lung cancer (NSCLC) remains to be identified. Experimental Design: A total of 385 adjacent normal lung tissues from patients with NSCLC were collected to determine FasL -844T/C polymorphism by PCR-based restriction fragment length polymorphism. FasL mRNA and protein expression in lung tumors were evaluated by real-time PCR and immunohistochemistry. The prognostic value of FasL -844T/C polymorphism on survival and relapse was determined by Kaplan-Meier analysis and Cox proportional hazards models. Results: The FasL -844CC genotype had higher prevalence in those with advanced tumors than in those with early tumors (P = 0.008). In addition, patients with the FasL -844CC genotype were more prone to tumor relapse than those with the FasL -844TT+TC genotype (62.1% vs. 37.9%, P = 0.001). Multivariate Cox regression analysis showed that patients with the FasL -844CC genotype had poorer survival in terms of overall survival (OS) and relapse-free survival (RFS) than those with the FasL -844TT+TC genotype (24.1 vs. 42.8 months for OS, HR = 1.455, P = 0.004; 15.4 vs. 31.4 months for RFS, HR = 1.710, P <0.001). Conclusions: FasL -844T/C polymorphism may predict survival and relapse in NSCLC. We suggest that FasL may be a molecular target for immunotherapeutic interventions to improve the clinical outcome of patients with NSCLC. This finding should be validated by another investigative group.

UR - http://www.scopus.com/inward/record.url?scp=80052825094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052825094&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-11-0227

DO - 10.1158/1078-0432.CCR-11-0227

M3 - Article

C2 - 21807637

AN - SCOPUS:80052825094

VL - 17

SP - 5991

EP - 5999

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 18

ER -